Thursday, July 02, 2020 12:10:08 PM
ENDRA Life Sciences Inc. (NDRA) Got You Down? Better Days Are Ahead
By
Wendy Andrews -
July 2, 2020
The stock of ENDRA Life Sciences Inc. (NASDAQ:NDRA) is now priced at $0.93 and the shares are -0.03 points down or -3.38% lower compared to its previous closing price of $0.96. The stock had 228253 contracts set over the past session. NDRA shares’ daily volume is compared to its average trading volume at 331438 shares. However, it has a float of 12.68 million and although its performance was -3.15% over the week, it’s one to watch. NDRA share price recently placing at $0.94 to $1.
The shorts are climbing into the ENDRA Life Sciences Inc. stock, with the latest data on short interest released on June 15, 2020, showing that short interest numbers in the NDRA shares have risen. Short interest in the stock represents just 4.89% of its float, but the volume has raised by 655. The volume of shorted shares rised to 620394 from 619739 shares over the last two weeks. The average intraday trading volume has been 335150 shares, which means that days to cover moved to roughly 1.851094.
In the last trading session, ENDRA Life Sciences Inc. (NASDAQ:NDRA) dropped by -$0.0302 over the week and lost -$0.0101 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $2.25. The stock recorded its established 52-week high on 01/06/20.
Since 04/06/20, the stock has traded to a low of $0.599 at 55.24%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 0. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, ENDRA Life Sciences Inc.’s two-week RSI is 49.5. This suggests that the stock is neutral at the moment and that NDRA shares’ price movement remains stable. The stochastic readings are equally revealing at 44.48% meaning the NDRA share price is currently in neutral territory.
The technical chart shows that the NDRA stock will likely settle at between $0.963 and $0.9962 per share. However, if the stock dips below $0.9037, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $0.8776.
Currently, the stock is trading in the red of MACD, with a reading of -0.0173. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
The average rating for the NDRA equity is 2 and is currently gathering a bullish momentum. Of 2 analysts tracking ENDRA Life Sciences Inc. polled by Reuters, 0 rated NDRA as a hold. The remaining 2 analysts were split evenly. However, the split wasn’t equal as a majority (2) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
The stocks P/S ratio currently stands at 0below the group’s average of 55.4. ENDRA Life Sciences Inc. has its P/E ratio at 5.5, which means that the stock is currently trading at a premium relative to the 5.3 industry average.
TAGS
ENDRA Life Sciences Inc.
NASDAQ:NDRA
NDRA
NDRA news
NDRA stock
"The Investors's Chief Problem--and even his worst enemy--is likely to be himself"
---Benjamin Graham
Recent NDRA News
- ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents • Business Wire • 05/02/2024 12:00:00 PM
- ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/28/2024 08:05:00 PM
- ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024 • Business Wire • 03/21/2024 12:00:00 PM
- ENDRA Life Sciences Installs First TAEUS System in the UK • Business Wire • 02/27/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:00:45 PM
- New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System • Business Wire • 02/21/2024 01:00:00 PM
- ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe • Business Wire • 02/14/2024 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/29/2023 10:07:32 PM
- ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology • Business Wire • 11/29/2023 01:00:00 PM
- ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference • Business Wire • 11/27/2023 01:00:00 PM
- ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update • Business Wire • 11/14/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:02:23 PM
- ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents • Business Wire • 11/08/2023 01:00:00 PM
- ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023 • Business Wire • 11/07/2023 09:05:00 PM
- ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023 • Business Wire • 11/06/2023 01:00:00 PM
- Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023 • Business Wire • 09/07/2023 12:00:00 PM
- ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA • Business Wire • 08/30/2023 12:00:00 PM
- ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents • Business Wire • 08/23/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:45:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:13:52 PM
- ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update • Business Wire • 08/14/2023 08:05:00 PM
- ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA • Business Wire • 08/14/2023 05:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 12:01:23 PM
- ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023 • Business Wire • 08/01/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM